Status:
COMPLETED
Simplification of Complex Insulin Regimens With Preserving Good Glycemic Control in Type 2 Diabetes
Lead Sponsor:
Bekes County Central Hospital
Collaborating Sponsors:
University of Debrecen
Szeged University
Conditions:
HBA1c
Body Weight
Eligibility:
All Genders
18+ years
Brief Summary
This study examines prospectively the safety and efficacy of switching from multiple daily insulin injections (MDI) to once daily IDegLira (insulin degludec and liraglutide fix ratio combination), a f...
Detailed Description
Type 2 diabetic patients suffering from severe hyperglycemia are often apply multiple daily insulin injections (MDI). If glucose toxicity resolves, the regimen may potentially be simplified, but there...
Eligibility Criteria
Inclusion
- Type 2 diabetic (T2D) patients \>18 years old
- detectable random, non-fasting serum C-peptide levels
- HbA1c=\< 7.5%
- treated with MDI (with stable daily doses of insulin at least for 90 days prior to baseline visit)
- using relatively low total daily insulin dose (TDD), at baseline visit low TDD is defined as TDD\<70 IU/day and TDD\<0.6 IU/kg/day at the same time.
Exclusion
- Type 1 diabetes
- treatment of T2D with any medication for diabetes other than insulin or metformin during 90 days before baseline visit
- active cancer
- anaemia (haemoglobin \<100g/l)
- acute or chronic kidney disease with an estimated glomerular filtration rate \<30 mL/min/1.73 m2
Key Trial Info
Start Date :
January 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2022
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04020445
Start Date
January 1 2016
End Date
January 1 2022
Last Update
February 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zoltán Taybani
Békéscsaba, Bekes County, Hungary, 5600